COMMUNIQUÉS West-GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences
28/10/2025
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Orion Group Interim Report January–September 2025
28/10/2025
ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million [...]
Upgrade of guidance
28/10/2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive trend in revenue and [...]
PL BioScience Announces new Board Member Ole Henrik Bang-Andreasen
28/10/2025
AACHEN, Germany, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion and manufacturing, [...]
Regeneron Reports Third Quarter 2025 Financial and Operating Results
28/10/2025
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024 Dupixent ® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD ® U.S. net sales increased 10% to $431 million [...]
KFSHRC inaugure la première usine de fabrication de thérapies géniques et cellulaires en Arabie saoudite
28/10/2025
RIYAD, Arabie saoudite, 28 oct. 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre a annoncé qu’il ouvrirait la première usine d’Arabie saoudite pour la fabrication de thérapies génétiques [...]
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
28/10/2025
Presentation will showcase the novel mechanisms of degradation of Amphista's Targeted Glues™, which recruit diverse E3 ligases, including DCAF16 and FBXO22, expanding the diversity and opportunity for TPD medicines. The [...]
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
28/10/2025
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel [...]
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
28/10/2025
CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman [...]
Zag Bio™ Launches with $80 Million Financing to Advance Thymus-targeted Medicines for Autoimmune Diseases
28/10/2025
Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanism to induce central tolerance Lead program in Type 1 diabetes is [...]
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
28/10/2025
BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans [...]
Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025
28/10/2025
DURHAM, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Verano Holdings Corp. Announces Shareholder Approval to Redomicile Parent Company from British Columbia to Nevada
28/10/2025
CHICAGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp . (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the plan the Company previously [...]
Castle Biosciences to Participate in Upcoming Investor Conferences
28/10/2025
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management [...]
Entrada Therapeutics to Present at Upcoming Investor Conferences
28/10/2025
BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in London [...]
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
28/10/2025
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and [...]
ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD
28/10/2025
Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic Solution ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE [...]
Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis
28/10/2025
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients GLASGOW, Scotland, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Causeway Therapeutics , a clinical-stage [...]
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
28/10/2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]

Pages